Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies

被引：128

作者：

Taylor, Ronald P. ^{[1
]}

Lindorfer, Margaret A. ^{[1
]}

机构：

[1] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA

来源：

CURRENT OPINION IN IMMUNOLOGY | 2008年 / 20卷 / 04期

关键词：

D O I：

10.1016/j.coi.2008.05.011

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The anti-CD20, B-cell-specific mAb rituximab (RTX) has been approved for treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis. Under conditions of high B cell burden, exhaustion of the body's effector mechanisms, for example, NK-cell-mediated killing, may lead to substantial decreases in the immunotherapeutic efficacy of this mAb. Moreover, RTX treatment of patients with chronic lymphocytic leukemia and high levels of circulating B cells can lead to removal of CD20 from the cells, thus allowing them to persist and resist clearance. RTX therapy for several autoimmune diseases has proven to be effective, but in numerous instances there has been little correlation between reductions in disease activity and changes in titers of pathogenic autoantibodies. This paradox may be explained by a separate mechanism: Binding of RTX to B cells generates immune complexes that act as decoys to attract monoycte/macrophages and thus reduce their inflammatory activity in certain autoantibody-mediated diseases. Several second-generation anti-CD20 mAbs with enhanced cytotoxic action have been developed and are being tested in the clinic for treatment of cancer and autoimmune diseases. The application of these mAbs, potentially in combination with immune effector modifying drugs, may successfully address the shortcomings of current anti-CD20 immunotherapy.

引用

页码：444 / 449

页数：6

共 55 条

[41] In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab [J].

Macor, Paolo ;

Tripodo, Claudio ;

Zorzet, Sonia ;

Piovan, Erich ;

Bossi, Fleur ;

Marzari, Roberto ;

Amadori, Alberto ;

Tedesco, Francesco .

CANCER RESEARCH, 2007, 67 (21) :10556-10563

[42] In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas [J].

Manches, O ;

Lui, G ;

Chaperot, L ;

Gressin, R ;

Molens, JP ;

Jacob, MC ;

Sotto, JJ ;

Leroux, D ;

Bensa, JC ;

Plumas, J .

BLOOD, 2003, 101 (03) :949-954

[43] Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity [J].

Masuda, Kazuhiro ;

Kubota, Tsuguo ;

Kaneko, Etsuji ;

Iida, Shigeru ;

Wakitani, Masako ;

Kobayashi-Natsume, Yukari ;

Kubota, Ai ;

Shitara, Kenya ;

Nakamura, Kazuyasu .

MOLECULAR IMMUNOLOGY, 2007, 44 (12) :3122-3131

[44]

REFF ME, 1994, BLOOD, V83, P435

[45] B-Cell-targeted therapy for systemic lupus erythematosus [J].

Sabahi, Ramin ;

Anolik, Jennifer H. .

DRUGS, 2006, 66 (15) :1933-1948

[46] Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand - An open-label trial [J].

Sfikakis, PP ;

Boletis, JN ;

Lionaki, S ;

Vigklis, V ;

Fragiadaki, KG ;

Iniotaki, A ;

Moutsopoulos, HM .

ARTHRITIS AND RHEUMATISM, 2005, 52 (02) :501-513

[47] Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis - Remission, relapse, and re-treatment [J].

Smith, K. G. C. ;

Jones, R. B. ;

Burns, S. M. ;

Jayne, D. R. W. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2970-2982

[48] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura [J].

Stasi, R ;

Pagano, A ;

Stipa, E ;

Amadori, S .

BLOOD, 2001, 98 (04) :952-957

[49] Drug Insight: the mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis [J].

Taylor, Ronald P. ;

Lindorfer, Margaret A. .

NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (02) :86-95

[50] The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 [J].

Teeling, Jessica L. ;

Mackus, Wendy J. M. ;

Wiegman, Luus J. J. M. ;

van den Brakel, Jeroen H. N. ;

Beers, Stephen A. ;

French, Ruth R. ;

van Meerten, Tom ;

Ebeling, Saskia ;

Vink, Tom ;

Slootstra, Jerry W. ;

Parren, Paul W. H. I. ;

Glennie, Martin J. ;

van de Winkel, Jan G. J. .

JOURNAL OF IMMUNOLOGY, 2006, 177 (01) :362-371

← 1 2 3 4 5 6 →